| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
222.95(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.39 - $21.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
53,265 |
53,265 |
74,223 |
229,905 |
| Total Sell Value |
$339,844 |
$339,844 |
$555,147 |
$3,944,931 |
| Total People Sold |
3 |
3 |
4 |
13 |
| Total Sell Transactions |
3 |
3 |
5 |
43 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Garen Jonathan |
Chief Business Officer |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,387 |
93,638 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,482 |
45,739 |
|
- |
|
| Mcmillan Scott T. |
Chief Operating Officer |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,032 |
5,032 |
|
- |
|
| Springhorn Jeremy P. |
Director |
– • – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
4,792 |
|
- |
|
| Cantor Maria E |
SVP, Investor Rel. & Comm. |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,188 |
92,439 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
4,792 |
|
- |
|
| Schaffer David |
Director |
– • – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
18,192 |
|
- |
|
| Kuta Alexander Edward Iii |
SVP, Regulatory Affairs |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,986 |
8,986 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
15,792 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
20,792 |
|
- |
|
| Astley-Sparke Philip |
Director |
– • – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
34,792 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2018-01-04 |
4 |
S |
$19.87 |
$431,069 |
D/D |
(21,690) |
447,559 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2018-01-03 |
4 |
S |
$20.13 |
$102,510 |
D/D |
(5,093) |
37,257 |
|
- |
|
| Firuta Paul E |
Chief Commercial Officer |
• – – |
2018-01-03 |
4 |
S |
$20.13 |
$118,028 |
D/D |
(5,864) |
85,251 |
|
- |
|
| Garen Jonathan |
Chief Business Officer |
• – – |
2018-01-03 |
4 |
S |
$20.13 |
$118,028 |
D/D |
(5,864) |
85,251 |
|
- |
|
| Cantor Maria E |
SVP, Investor Relations & Comm |
• – – |
2018-01-03 |
4 |
S |
$20.13 |
$118,028 |
D/D |
(5,864) |
85,251 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2017-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
19,350 |
42,350 |
|
- |
|
| Garen Jonathan |
Chief Business Officer |
• – – |
2017-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
56,115 |
56,115 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2017-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
271,185 |
271,185 |
|
- |
|
| Firuta Paul E |
Chief Commercial Officer |
• – – |
2017-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
56,115 |
56,115 |
|
- |
|
| Cantor Maria E |
SVP, Investor RelationsSVP, In |
• – – |
2017-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
56,115 |
56,115 |
|
- |
|
| Petry Harald |
Chief Scientific Officer |
• – – |
2017-06-29 |
4 |
AS |
$6.02 |
$129,709 |
D/D |
(21,547) |
0 |
|
- |
|
| Petry Harald |
Chief Scientific Officer |
• – – |
2017-06-29 |
4 |
OE |
$3.50 |
$75,430 |
D/D |
21,547 |
21,547 |
|
- |
|
| Petry Harald |
Chief Scientific Officer |
• – – |
2017-06-28 |
4 |
AS |
$6.01 |
$166,859 |
D/D |
(27,753) |
0 |
|
- |
|
| Petry Harald |
Chief Scientific Officer |
• – – |
2017-06-28 |
4 |
OE |
$3.49 |
$96,933 |
D/D |
27,753 |
27,753 |
|
- |
|
336 Records found
|
|
Page 13 of 14 |
|
|
0.06 (1.18%) 
